More frequently reported side effects include: increased serum alanine aminotransferase, increased serum amylase, increased serum aspartate aminotransferase, and neutropenia.
See below for a comprehensive list of adverse effects.
The most common side effects reported during any of 3 large controlled clinical trials were headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, and rhinitis.
During 2 clinical trials, the most common side effects associated with emtricitabine in combination with other antiretrovirals were headache, diarrhea, nausea, and rash.
Most were of mild to moderate severity.
Treatment was discontinued due to these adverse effects in approximately 1% of patients.
Side effects have been reported for emtricitabine when taken in combination with other antiretroviral agents.
Dermatological side effects have included rash event (any Grade: up to 30%; Grades 2 to 4: 7%).
"Rash event" included rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash, exfoliative rash, generalized rash, macular rash, pruritic rash, vesicular rash, and allergic reaction.
Skin discoloration (palmar-plantar hyperpigmentation) has been reported.
Nervous system side effects have included dizziness (any Grade: up to 25%; Grades 2 to 4: 8%), headache (any Grade: up to 22%; Grades 2 to 4: 6%), insomnia (any Grade: up to 16%; Grades 2 to 4: 5%), paresthesia (any Grade: up to 6%), neuropathy/peripheral neuritis (any Grade: 4%), and somnolence.
Gastrointestinal side effects have included diarrhea (any Grade: 23%; Grades 2 to 4: 9%), nausea (any Grade: up to 18%; Grades 2 to 4: 9%), vomiting (any Grade: 9%; Grades 2 to 4: 2%), and dyspepsia (any Grade: up to 8%).
Metabolic side effects have included blood glucose changes (less than 40 or greater than 250 mg/dL; up to 3%), hyperglycemia (greater than 250 mg/dL; 2%), and increased fasting cholesterol (greater than 240 mg/dL; 22%), triglycerides (greater than 750 mg/dL; up to 10%), serum amylase (greater than 2 times ULN: up to 5%; greater than 175 units/L: 8%), fasting triglycerides (greater than 750 mg/dL; 4%), pancreatic amylase (greater than 2 times ULN; up to 2%), serum lipase (greater than 2 times ULN; up to 1%), and alkaline phosphatase (greater than 550 units/L; 1%).
Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy.
Respiratory side effects have included rhinitis (any Grade: up to 18%), increased cough (any Grade: 14%), sinusitis (Grades 2 to 4: 8%), upper respiratory tract infections (Grades 2 to 4: 8%), and nasopharyngitis (Grades 2 to 4: 5%).
Other side effects have included asthenia (any Grade: up to 16%), abdominal pain (any Grade: up to 14%), and fatigue (Grades 2 to 4: 9%).
Increased creatine kinase (greater than 990 units/L in males and 845 units/L in females) has been reported in 9% of patients.
Musculoskeletal side effects have included elevated creatine kinase (greater than 4 times ULN; up to 12%), myalgia (any Grade: up to 6%), and arthralgia (any Grade: up to 5%).
Psychiatric side effects have included abnormal dreams (any Grade: up to 11%), depressive disorders (any Grade: up to 9%), and depression (Grades 2 to 4: 9%).
Hepatic side effects have included elevated AST (greater than 5 times ULN; up to 6%), ALT (greater than 5 times ULN; up to 5%), and bilirubin (greater than 2.
5 times ULN; up to 1%).
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of emtricitabine and other nucleoside analogs alone or in combination with other antiretroviral agents.
Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and hepatitis B after discontinuation of emtricitabine and were associated with liver failure and liver decompensation in some patients.
Increased AST (greater than 180 units/L in males and 170 units/L in females) has been reported in 3% of patients.
Increased ALT (greater than 215 units/L in males and 170 units/L in females) has been reported in 2% of patients.
Immunologic side effects have included immune reconstitution syndrome.
Autoimmune disorders (e.
g.
, Graves' disease, polymyositis, and Guillain-Barre syndrome) have been reported in the setting of immune reconstitution.
Hematologic side effects have included decreased neutrophils (less than 750/mm3; up to 5%).
Genitourinary side effects have included hematuria (greater than 75 RBC/HPF; 3%) and glycosuria (3 plus; less than 1%).
Burning, crawling, itching, numbness, prickling, "pins and needles‚Äù, or tingling feelings
chest pain or tightness
cough or hoarseness
fever or chills
lower back or side pain
painful or difficult urination
pale skin
troubled breathing with exertion
unusual bleeding or bruising
unusual tiredness or weakness
Sensation of pins and needles
stabbing pain
Abdominal or stomach pain
abnormal dreams
darkening or redness of the skin
depression
dizziness
earache
headache
heartburn or indigestion
itching skin
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
rash, hives, or welts on the skin
spots on your skin resembling a blister or pimple
vomiting
Joint pain or swelling
muscle stiffness
trouble sleeping
unsteadiness or awkwardness
weakness in the arms, hands, legs, or feet